Pentoxifylline downregulates nitric oxide and tumor necrosis factor-α induced by mycobacterial lipoarabinomannan in a macrophage cell line

International Journal of Leprosy and Other Mycobacterial Diseases

Volumn 69, Issue 3, 2001, Pages 225-233

  Park, Eunkyue ^a   Schuller Levis, Georgia ^a   Park, Seung Yong ^b   Jia, Jun Hua ^a   Levis, William R ^a,c   Kim, C ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b Konkuk University   (South Korea)

^c STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GAMMA INTERFERON; LIPOARABINOMANNAN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRITE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA NODOSUM LEPROSUM; IC 50; IN VITRO STUDY; MACROPHAGE; MOUSE; MYCOBACTERIUM; NONHUMAN; NORTHERN BLOTTING; WESTERN BLOTTING;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MYCOBACTERIUM LEPRAE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035718301     PISSN: 0148916X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. A reagent for the single step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples
2. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages
3. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages
4. Pentoxifylline suppression of tumor necrosis factor gene transcription
5. An open study of the anti-TNF alpha agent pentoxifylline in the treatment of rheumatoid arthritis
6. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria
7. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points on the signaling pathway
8. Treatment of endotoxic shock: Glucocorticoids, lazaroids, nonsteroidals, others
9. Molecular mechanisms of dexamethasone inhibition of nitric oxide synthase expressed in interleukin 1 beta-stimulated mesangial cells: Evidence for the involvement of transcriptional and post-transcriptional regulation
10. Effect of pentoxifylline on nitric oxide released by murine macrophages
11. Treatment of leprosy in the United States
12. Differential effects of pentoxifylline and interleukin-10 on production of tumor necrosis factor and inducible nitric oxide synthase by murine macrophages
13. Th1-Th2 paradigm: Insights from leprosy
14. Nitric oxide as a secretory product of mammalian cells
15. The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy
16. Pentoxifylline in vivo downregulates the release of IL-1β, IL-6, IL-8 and tumor necrosis factor-α by human peripheral blood mononuclear cells
17. Taurine chloramine inhibits synthesis of nitric oxide and the release of tumor necrosis factor in activated RAW 264.7 cells
18. Taurine chloramine inhibits production of nitric oxide and TNF-α in activated RAW 264.7 cells by mechanisms that involve transcriptional and translational events
19. Therapeutic potential for cytokine agonists: Thalidomide and pentoxifylline in Hansen's Disease
20. Nitric oxide and the cutis
21. Pentoxifylline to treat Mycobacteium avium complex exacerbation in late-stage HIV infection
22. Classification of leprosy according to immunity. A five-group system
23. Macrophage activation: Lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes cfos, KC, JE, and tumor necrosis factor-α
24. Pentoxifylline
25. The influence of thalidomide on the clinical and immunological manifestations of erythema nodosum leprosum
26. Pentoxifylline decreases in vivo and in vitro tumour necrosis factor-alpha (TNF-alpha) production in lepromatous leprosy patients with erythema nodosum leprosum (ENL)
27. Is pentoxifylline a viable alternative in the treatment of ENL?
28. Mycobacterial lipoarabinomannan induces nitric oxide and tumor necrosis factor alpha production in a macrophage cell line: Down-regulation by taurine chloramine
29. Pentoxifylline suppresses irritant and contact hypersensitivity reactions
30. Pentoxifylline suppresses allergic patch test reaction in humans
31. Pentoxifylline blocks the elicitation phase of contact hypersensitivity and irritant dermatitis
32. Cytokine patterns at the site of mycobacterial infection
33. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline
34. Production of tumor necrosis factor-α by resident and activated murine macrophages
35. Pentoxifylline may be useful in the treatment of type 2 leprosy reaction
36. Cell-specific effects of pentoxifylline on nitric oxide production and inducible nitric oxide synthase mRNA expression
37. Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjuvant therapy
38. Pentoxyfylline